Literature DB >> 35757972

GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.

Petros Petrikis1, Alexandra Polyzou2, Kyriaki Premeti2, Argyro Roumelioti2, Andreas Karampas1, Georgios Georgiou1, Dionysios Grigoriadis3, George Leondaritis2,4.   

Abstract

BACKGROUND AND HYPOTHESIS: Schizophrenia is characterized by a complex interplay between genetic and environmental risk factors converging on prominent signaling pathways that orchestrate brain development. The Akt/GSK3β/mTORC1 pathway has long been recognized as a point of convergence and etiological mechanism, but despite evidence suggesting its hypofunction, it is still not clear if this is already established during the first episode of psychosis (FEP). STUDY
DESIGN: Here, we performed a systematic phosphorylation analysis of Akt, GSK3β, and S6, a mTORC1 downstream target, in fresh peripheral blood mononuclear cells from drug-naive FEP patients and control subjects. STUDY
RESULTS: Our results suggest 2 distinct signaling endophenotypes in FEP patients. GSK3β hypofunction exhibits a promiscuous association with psychopathology, and it is normalized after treatment, whereas mTORC1 hypofunction represents a stable state.
CONCLUSIONS: Our study provides novel insight on the peripheral hypofunction of the Akt/GSK3β/mTORC1 pathway and highlights mTORC1 activity as a prominent integrator of altered peripheral immune and metabolic states in FEP patients.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Akt; S6; anti- psychotics; inflammation; insulin; mTOR

Mesh:

Substances:

Year:  2022        PMID: 35757972      PMCID: PMC9434466          DOI: 10.1093/schbul/sbac069

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   7.348


  47 in total

1.  Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum.

Authors:  Santiago G Lago; Jakub Tomasik; Geertje F van Rees; Marina Rubey; Emiliano Gonzalez-Vioque; Jordan M Ramsey; Frieder Haenisch; Jantine A Broek; Javier Vázquez-Bourgon; Sergi Papiol; Paula Suarez-Pinilla; Tillmann Ruland; Bonnie Auyeug; Olya Mikova; Nikolett Kabacs; Volker Arolt; Simon Baron-Cohen; Benedicto Crespo-Facorro; Sabine Bahn
Journal:  Brain Behav Immun       Date:  2020-09-06       Impact factor: 7.217

2.  Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia.

Authors:  Masayuki Ide; Tetsuo Ohnishi; Miyuki Murayama; Izuru Matsumoto; Kazuo Yamada; Yoshimi Iwayama; Irina Dedova; Tomoko Toyota; Takashi Asada; Akihiko Takashima; Takeo Yoshikawa
Journal:  J Neurochem       Date:  2006-10       Impact factor: 5.372

Review 3.  Schizophrenia.

Authors:  René S Kahn; Iris E Sommer; Robin M Murray; Andreas Meyer-Lindenberg; Daniel R Weinberger; Tyrone D Cannon; Michael O'Donovan; Christoph U Correll; John M Kane; Jim van Os; Thomas R Insel
Journal:  Nat Rev Dis Primers       Date:  2015-11-12       Impact factor: 52.329

4.  Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients.

Authors:  Nico J M van Beveren; Gabrielle H S Buitendijk; Sigrid Swagemakers; Lianne C Krab; Christian Röder; Lieuwe de Haan; Peter van der Spek; Ype Elgersma
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

Review 5.  The neurobiology and treatment of first-episode schizophrenia.

Authors:  R S Kahn; I E Sommer
Journal:  Mol Psychiatry       Date:  2014-07-22       Impact factor: 15.992

6.  Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells.

Authors:  N Bartolotti; D A Bennett; O Lazarov
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

Review 7.  GSK3: A Kinase Balancing Promotion and Resolution of Inflammation.

Authors:  Leonie Hoffmeister; Mareike Diekmann; Korbinian Brand; René Huber
Journal:  Cells       Date:  2020-03-28       Impact factor: 6.600

8.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Authors:  Antonio F Pardiñas; Peter Holmans; Andrew J Pocklington; Valentina Escott-Price; Stephan Ripke; Noa Carrera; Sophie E Legge; Sophie Bishop; Darren Cameron; Marian L Hamshere; Jun Han; Leon Hubbard; Amy Lynham; Kiran Mantripragada; Elliott Rees; James H MacCabe; Steven A McCarroll; Bernhard T Baune; Gerome Breen; Enda M Byrne; Udo Dannlowski; Thalia C Eley; Caroline Hayward; Nicholas G Martin; Andrew M McIntosh; Robert Plomin; David J Porteous; Naomi R Wray; Armando Caballero; Daniel H Geschwind; Laura M Huckins; Douglas M Ruderfer; Enrique Santiago; Pamela Sklar; Eli A Stahl; Hyejung Won; Esben Agerbo; Thomas D Als; Ole A Andreassen; Marie Bækvad-Hansen; Preben Bo Mortensen; Carsten Bøcker Pedersen; Anders D Børglum; Jonas Bybjerg-Grauholm; Srdjan Djurovic; Naser Durmishi; Marianne Giørtz Pedersen; Vera Golimbet; Jakob Grove; David M Hougaard; Manuel Mattheisen; Espen Molden; Ole Mors; Merete Nordentoft; Milica Pejovic-Milovancevic; Engilbert Sigurdsson; Teimuraz Silagadze; Christine Søholm Hansen; Kari Stefansson; Hreinn Stefansson; Stacy Steinberg; Sarah Tosato; Thomas Werge; David A Collier; Dan Rujescu; George Kirov; Michael J Owen; Michael C O'Donovan; James T R Walters
Journal:  Nat Genet       Date:  2018-02-26       Impact factor: 38.330

9.  Altered expression of mRNA profiles in blood of early-onset schizophrenia.

Authors:  Yong Xu; Yin Yao Shugart; Guoqiang Wang; Zaohuo Cheng; Chunhui Jin; Kai Zhang; Jun Wang; Hao Yu; Weihua Yue; Fuquan Zhang; Dai Zhang
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

10.  Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia.

Authors:  Inés Ibarra-Lecue; Rebeca Diez-Alarcia; Benito Morentin; J Javier Meana; Luis F Callado; Leyre Urigüen
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.